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Core binding factor (CBF), also known as polyomavirus enhancer-binding protein 2 and SL3 enhancer factor
1, is a mammalian transcription factor that binds to an element termed the core within the enhancers of the
murine leukemia virus family of retroviruses. The core elements of the SL3 virus are important genetic
determinants of the ability of this virus to induce T-cell lymphomas and the transcriptional activity of the viral
long terminal repeat in T lymphocytes. CBF consists of two subunits, a DNA binding subunit, CBF a, and a
second subunit, CBF b, that stimulates the DNA binding activity of CBF a. One of the genes that encodes a
CBF a subunit is AML1, also called Cbfa2. This locus is rearranged by chromosomal translocations in human
myeloproliferative disorders and leukemias. An exogenously expressed Cbfa2-encoded subunit (CBFa2-451)
stimulated transcription from the SL3 enhancer in P19 and HeLa cells. Activity was mediated through the core
elements. Three different isoforms of CBF b were also tested for transcriptional activity on the SL3 enhancer.
The longest form, CBF b-187, increased the transcriptional stimulation by CBFa2-451 twofold in HeLa cells,
although it had no effect in P19 cells. Transcriptional activation by CBF b required binding to the CBF a
subunit, as a form of CBF b that lacked binding ability, CBF b-148, failed to increase activity. These results
indicated that at least in certain cell types, the maximum activity of CBF required both subunits. They also
provided support for the hypothesis that CBF is a factor in T lymphocytes that is responsible for recognition
of the SL3 cores. We also examined whether CBF could distinguish a 1-bp difference between the enhancer core
of SL3 and the core of the nonleukemogenic virus, Akv. This difference strongly affects transcription in T cells
and leukemogenicity of SL3. However, no combination of CBF a and CBF b subunits that we tested was able
to distinguish the 1-bp difference in transcription assays. Thus, a complete understanding of how T cells
recognize the SL3 core remains to be elucidated.
Core binding factor (CBF) is a transcription factor initially
identified as a cellular factor that binds to enhancers of several
viruses and cellular genes. CBF binds to an element termed the
enhancer core (4, 18, 41, 46, 48, 51) within the genomes of
mammalian type C retroviruses (10). It also binds to similar
elements within the enhancers of polyomavirus and several
cellular genes, including those encoding the T-cell receptor
(TCR) b, g, and d chains, the immunoglobulin heavy chain,
CD3-ε, and CD3-d, interleukin-3, and myeloperoxidase (6, 14,
15, 17, 35, 37, 45, 49, 51). CBF is also called polyomavirus
enhancer-binding protein 2 (PEBP2) (17), SL3 enhancer factor
1 (46), and SL3/Akv core binding factor (4).
CBF is composed of two heterologous subunits, CBF a and
CBF b. cDNAs encoding both subunits of CBF have recently
been cloned. There are at least three related mammalian genes
that encode CBF a subunits. One, called AML1 or Cbfa2, was
originally cloned from a common translocation breakpoint in
patients with acute myelogenous leukemia (AML) of the M2
subtype (28). The reciprocal 8;21 translocation results in the 59
portion of AML1 being fused in frame to sequences on chro-
mosome 8 termed ETO or MTG8 (9, 27). Subsequently, 3;21
translocations that occur in therapy-related AML, myelodys-
plastic syndrome, or blast crisis of chronic myelogenous leu-
kemia were also found to result in rearrangments at the AML1
locus (31, 38). One type of t(3;21) results in the 59 portion of
AML1 being fused to a gene encoding a ribosomal protein
(EAP/L22) on chromosome 3 such that EAP sequences in the
fusion protein are read out of frame (30). Another type of
t(3;21) results in fusion of the 59 portion of AML1 to the entire
EVI-1 coding sequence (26). cDNA clones encoding the mouse
homolog of AML1, called PEBP2aB, were shown to encode
proteins that bound to the polyomavirus enhancer (2). In ad-
dition, the human AML1-encoded protein was shown to bind
to the enhancer core consensus sequence (25, 34). These re-
sults confirmed that AML1/PEBP2aB encodes a CBF a sub-
unit.
Two additional genes encode CBF a subunits: Cbfa1
(Pebpa2a, AML3) and Cbfa3 (Pebpa2c, AML2) (1, 2, 20, 34,
52). Each of the three CBF a-subunit genes encodes a stretch
of 128 amino acids called the Runt domain that is highly
homologous to a portion of the Drosophila segmentation pair-
rule gene, runt (8, 9, 16, 34). The Runt domain mediates DNA
binding (16, 25, 34). As a result of alternative splicing, multiple
forms of the CBF a proteins are encoded by both the Cbfa2
and Cbfa1 genes (2, 16, 34). A third gene, AML2 or Cbfa3, that
encodes a CBF a subunit was identified on the basis of se-
quence homology (20).
While the transcriptional properties of CBF a have been
studied, less is known about the in vivo function of the CBF b
subunit. CBF b was initially identified as a protein that copu-
rified with CBF a (17, 33, 50). Unrelated to any known genes,
CBF b is encoded by a single gene called CBF b (Pebp2b) (33,
50). There are at least four forms of CBF b due to alternative
splicing (33, 50). None are capable of binding DNA. However,
some forms of CBF b have been shown to interact with CBF a
in vitro and increase its affinity for DNA (33, 50). The inter-
action of the two heterologous subunits is mediated through
* Corresponding author. Mailing address: Department of Molecular
Genetics, Albert Einstein College of Medicine, 1300 Morris Park Ave.,
Bronx, NY 10461. Phone: (718) 430-3715. Fax: (718) 430-8778. Elec-
tronic mail address: lenz@aecom.yu.edu.
2898
the Runt domain of CBF a (16, 25, 34). Interestingly, the CBF
b gene has also been implicated in AML (21). A pericentric
inversion of chromosome 16 [inv(16)(p13q22)] that is charac-
teristically observed in humans with AML of the M4 eosinophil
subtype results in fusion of CBF b to a smooth muscle myosin
heavy-chain gene,MYH11. This inversion results in a transcript
encoding a fusion protein in which the first 165 amino acids of
CBF b are linked to a variable length portion of the carboxyl
tail of the myosin chain.
Both the Cbfa1- and Cbfa2-encoded forms of CBF a have
been shown recently to have transcriptional activity on the
TCR b enhancer in cotransfection assays (2, 34). We wished to
determine whether it is also active on the enhancer core se-
quences that are present in the long terminal repeats (LTRs)
of the murine leukemia virus (MuLV) family of retroviruses.
MuLV enhancer cores are critical genetic determinants of viral
leukemogenicity. Mutation of 2 bp in the core of Moloney
MuLV changed the leukemogenic specificity of the virus from
thymic lymphoma to erythroleukemia (42). Mutation of 3 bp in
each of four enhancer cores of SL3-3 (SL3) strongly reduced
the capacity of this virus to induce T-cell lymphomas (13). A
1-bp difference between the enhancer cores of SL3 and a
highly homologous, nonleukemogenic MuLV, Akv, also signif-
icantly reduced viral leukemogenicity (29) and the transcrip-
tional activity of the SL3 LTR specifically in T lymphocytes (4).
As both the Cbfa1 and Cbfa2 genes are expressed in T lym-
phocytes (3, 34, 39), we tested whether the CBF a subunit
encoded by the mouse Cbfa2 gene is transcriptionally active on
the MuLV enhancer cores. In particular, we asked whether it
could distinguish the 1-bp difference between the SL3 and Akv
cores. We also tested the activity of CBF b in transcription
assays.
MATERIALS AND METHODS
Cell lines. HeLa cells were grown in minimal essential medium supplemented
with 10% fetal calf serum, 100 U of penicillin per ml, 10 mg of streptomycin per
ml, and 2 mM glutamine. P19 is a mouse embryonal carcinoma cell line. P19 cells
were grown in Dulbecco’s modified Eagle medium with the same supplements.
Both lines were grown at 378C in 100% humidity. HeLa cells were grown under
5% CO2, while P19 cells were grown with 7.5% CO2. L691 cells were grown in
the same conditions as P19 cells.
Plasmids. The reporter plasmids SL3 and SAA have been previously described
(19, 29, 40). The mutated reporter plasmids Mut. core I, Mut. core II, and Mut.
core I & II were constructed by using PCR-based mutagenesis. Primers contain-
ing the appropriately altered bases (Fig. 1) and convenient restriction sites were
synthesized and purified. The upstream primer, 59 AGTATCCTCGAGGCTG
CAGTAACGCCATTTTGCAAGGCAT 39, was derived from the 59 end of the
U3 region of SL3. This primer contained an XhoI site corresponding to the XhoI
site in the SL3-chloramphenicol acetyltransferase (CAT) plasmid (Fig. 1). The
downstream primer was derived from the SL3 enhancer in a region spanning the
corresponding core elements (Fig. 1). The sequence of the primer for Mut. core
I was 59 TGGGCCGGGGCCCTAGTGCTTAACGGCAGATATCCTGTCGT
TAGCGGTCTGGGGACCATC 39. The sequence of the primer used to make
Mut. core II and Mut. core I & II was 59 GCTTAACGGCAGATATCCTGTC
GTTAGCGTGATGGGGACCATCTGTTCTTGGCCCTGGG 39. The under-
lined bases indicate the mutated nucleotides relative to wild-type SL3. The
downstream primer for Mut. core I contained an ApaI site, while that for Mut.
core II and Mut. core I & II had an EcoRV site corresponding to sites present
in the SL3 enhancer. PCR was then performed with these purified primers on a
wild-type SL3 LTR or a core I mutant LTR template. As the enhancer had two
tandem 72-bp repeats, conditions were optimized to obtain a high percentage of
products in which the sites were mutated in both repeats of the enhancer. PCR
cycling conditions were 1 cycle at 958C for 2 min followed by 30 cycles at 958C for
1 min and 728C for 2 min. The PCR products were then resolved by electro-
phoresis and cut with either XhoI-ApaI or XhoI-EcoRV. ApaI and EcoRV cut
the enhancer once in each 72-bp repeat. Thus, the digestion cleaved the PCR
product into two major fragments, an XhoI-ApaI 162-bp piece or XhoI-EcoRV
141-bp piece and an ApaI-ApaI or EcoRV-EcoRV 72-bp piece. The larger piece
was inserted into a subclone of the SL3 LTR in pSP73 (Promega), creating an
LTR with a single 72-bp unit. The 72-bp fragment was then inserted into the
subclone, yielding tandem 72-bp repeats. The modified LTRs were subsequently
excised and inserted into the CAT plasmid. The clones were sequenced at every
step to ensure that they were identical to the parental sequence except for the
mutated bases.
A 2,047-bp fragment of CBFa2-451 containing the entire open reading frame
was subcloned between the HindIII and BglII sites of plasmid pRSV-b-globin
(obtained from the American Type Culture Collection), replacing the b-globin
gene. CBFa2-451 was expressed from the Rous sarcoma virus (RSV) promoter
and enhancer. cDNAs encoding the CBF b subunits (CBF b-187, CBF b-182,
and CBF b-148) were also subcloned into the modified RSV expression vector.
All plasmids for transfections of mammalian cells were purified by using
Qiagen columns.
Transfections and CAT assays. Transient transfections of P19 and HeLa cells
were performed by using an optimized Lipofectin (GIBCO BRL) protocol. Cells
were plated at a density of 106/60-mm2 plate 24 h before transfection. The
manufacturer’s protocol was then followed, using a total of 8 mg of DNA (1.5 mg
of CAT reporter, 1.5 mg of a simian virus 40-luciferase internal control, and up
to 5 mg of CBF subunit) plus 25 ml of Lipofectin per transfection. When lower
amounts of plasmid were used, pBluescript DNA was included so that the
amount of DNA in every culture was the same. The medium was changed after
a 6-h incubation. The cells were harvested after 30 h, and lysates were prepared
as previously described (4, 40). Transfections of L691 cells were performed by
the DEAE-dextran method as previously described (43).
The concentration of protein in the lysate was then determined by the Bio-Rad
protein assay kit. An aliquot of the lysate was then used to measure CAT
enzymatic activity as previously described (11, 40). In addition, another aliquot of
lysate was used to determine the luciferase activity from the internal control
plasmid (5). In HeLa cells, CAT activity was normalized to these values. In P19
cells, we were unable to obtain usable measurements of luciferase activity. With
the simian virus 40 early enhancer/promoter driving luciferase expression, activ-
ity was found to decrease about 10-fold at the highest concentration of CBFa2-
451 expression plasmid used. Two other luciferase constructs, one with the
mouse mammary tumor virus LTR with the negative regulatory element in U3
deleted and the other with a sea urchin embryonic histone gene promoter,
resulted in no detectable activity. Therefore, to avoid overestimating the stimu-
lation by CBFa2-451, the luciferase internal control was not used in comparing
different transfections in P19 cells. CAT activities were determined by Phosphor-
Imager analysis of thin-layer chromatography plates, and the percentage of
chloramphenicol acetylated was calculated. The level of transactivation by CBF
was then calculated by dividing the activity of the LTR-CAT plasmid (normalized
to luciferase activity in HeLa cells) in the presence of CBF by the level of activity
in a parallel sample without CBF. Multiple trials were performed for each
FIG. 1. Schematic representation of sequences within plasmids used in these
studies. (A) The reporter plasmid used in cotransfection assays. SL3 LTR se-
quences, shown in black, include 443 bp of the U3 region upstream of the
transcriptional initiation site at the U3/R junction plus 32 bp of the R region.
These are positioned upstream of the cat gene. The full-size arrows under the
enhancer denote the tandem, 72-bp repeats that comprise the enhancer. The
small arrow denotes a third partial repeat. The expanded view of part of one
repeat shows the sequences and orientations of the two core elements within a
single repeat. Underneath the core I sequence is the single nucleotide difference
found in the core element of Akv virus (SAA). In addition, the nucleotides that
were changed in the core element mutations are shown. (B) General schematic
diagram of all constructs used to express the multiple subunits of CBF. The
cDNA encoding a particular subunit was placed downstream of the RSV LTR.
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experiment. The means were calculated and plotted. Standard deviations were
calculated and plotted for each mean, using the STDEVP program of Microsoft
Excel.
Expression and partial purification of the DNA binding domain of CBFa2-
451. A DNA fragment encoding a 17-kDa DNA binding (Runt) domain from the
mouse CBFa2-451 protein (amino acids 51 to 202) was amplified by PCR using
a 59 (sense) primer (CGGAATTCCCATATGGTGGAGGTACTAGCT) and a
39 (antisense) primer (CGGATCCTTACTCCAATTCACTGAGCCG). The am-
plified fragment was digested with NdeI and BamHI and subcloned into the
NdeI-BamHI sites of a modified pET3 vector lacking the codons of T7 gene 10
(32). This synthetic DNA contains a methionine codon in the context of the NdeI
site in frame with the first amino acid of the DNA binding domain.
For expression and purification, the plasmid was transformed into Escherichia
coli BL21(DE3) containing plasmid pLysS (1). Expression was induced with 1
mM isopropylthiogalactopyranoside (IPTG) for 3 h at 378C (A600 5 0.7 to 0.9 at
time of induction and 1 to 1.5 at time of harvest). The bacterial cell pellet from
a 1-liter culture was resuspended in equal-weight lysis buffer (10% sucrose, 50
mM Tris-HCl [pH 7.5]), protease inhibitors [1 mM Pefabloc, 1 mM phenyl-
methylsulfonyl fluoride, 50 mM calpain inhibitor 1, 1 mg of leupeptin per ml, 1 mg
of pepstatin A per ml, 2 mg of aprotinin per ml]). Cells were frozen by being
dropped directly into liquid nitrogen, thawed in a room temperature water bath,
incubated on ice in the presence of 400 mg of lysozyme per ml and 0.1 M
ammonium sulfate for 30 min, and then lysed with gentle agitation for 3 min at
378C. Samples were centrifuged at 40,000 3 g for 1 h at 48C. Soluble proteins
were dialyzed against 200 volumes of buffer A (150 mM KCl, 20 mM imidazole
[pH 7.0], 20 mM b-mercaptoethanol). After dialysis, samples were applied to a
DEAE-Sephacel column (24 ml) equilibrated in buffer A. The column was
washed with 1.5 column volumes buffer A, and approximately 2-ml fractions were
collected. Flowthrough fractions containing core binding activity were pooled
and dialyzed against 200 volumes buffer B (50 mM NaCl, 20 mM N-2-hydroxy-
ethylpiperazine-N9-2-ethanesulfonic acid [HEPES; pH 7.5], 20 mM b-mercapto-
ethanol, 10% glycerol, 0.05% Triton X-100) and then applied to a P-11 cellulose
phosphate column (3 ml; Whatman) equilibrated in buffer B. Core binding
activity was eluted with a 30-ml linear gradient of NaCl from 50 mM to 1.0 M in
buffer B. Approximately 1-ml fractions were collected. Fractions with peak ac-
tivity were pooled, exchanged into buffer C [50 mM NaCl, 20 mM 2-(N-mor-
pholino) ethanesulfonic acid (pH 6.5), 20 mM b-mercaptoethanol, 10% glycerol,
0.05% Triton X-100] on a Sephadex G-25 column, and then applied to a Mono
S column (Pharmacia). Bound protein was eluted with a 60-ml linear gradient
from 50 mM to 1.0 M NaCl. Active fractions were pooled, and glycerol was
added to a final concentration of 20%. The DNA binding domain 51-202 was
estimated to be 20 to 30% pure by Coomassie brilliant blue staining of a sodium
dodecyl sulfate-polyacrylamide gel.
Protein-DNA binding analysis. Complementary 18-bp oligonucleotides con-
taining the SL3 and Akv core site (4), the high-affinity core site deduced by
Thornell et al. (47) and Wang and Speck (49), and a mutant core site (see Fig.
4C for sequences) were synthesized on a Biosearch Cyclone DNA synthesizer at
Dartmouth Medical School and purified by electrophoresis through 20% poly-
acrylamide–7 M urea gels (not shown).
32P-labeled DNA probes and electrophoretic mobility shift assays (EMSAs)
were performed as described previously (49, 50). Binding reaction mixtures
contained 20,000 cpm of 32P-end-labeled high-affinity-site probe, 0.5 mg of
poly(dI-dC) z poly(dI-dC), and 0.5 ml of protein sample, in the presence of
various concentrations of the SL3, Akv, or high-affinity mutant core site com-
petitor. The data were scanned and analyzed with the NIH Image program.
RESULTS
Transcriptional activity of CBF a on an MuLV enhancer.
We tested the ability of the CBF a subunit encoded by the
murine Cbfa2 gene to transactivate the LTR of the T-cell
lymphomagenic MuLV, SL3. The CBFa2-451 cDNA encodes
a 451-amino-acid polypeptide identical to PEBP2aB1 (2, 3, 7).
A schematic representation of this cDNA is shown in Fig. 2.
The CBFa2-451 cDNA was cloned into an expression vector
downstream of the RSV LTR and cotransfected with a plasmid
containing the SL3 LTR upstream of the bacterial reporter
gene cat (Fig. 1). The SL3 LTR enhancer is composed of two
72-bp repeats. As shown in Fig. 1A, there are two different core
elements to which CBF binds in each repeat, making a total of
four CBF binding sites in the SL3 enhancer. The two cores
within each repeat are not identical and are in inverse orien-
tation relative to each other, separated by 14 bp. Thornell et al.
(47) termed these sites I and II (Fig. 1A) and estimated that
CBF from mouse T cells bound about five times more strongly
to core I.
The activity of CBFa2-451 was tested in two cell lines, HeLa
and P19 (Fig. 3). P19 cells were chosen because the Cbfa2 gene
is not expressed in these cells and both Cbfa1 and Cbfa2 have
been shown to transactivate the TCR b enhancer when ex-
pressed exogenously in this cell line (2). HeLa cells were cho-
sen empirically as another type of cells which also supported
CBF activity. In both lines, CBFa2-451 stimulated transcrip-
tion from the SL3 LTR. Maximum stimulation was about
eightfold in HeLa cells and sixfold in P19 cells. As a control,
the empty RSV vector was tested. The RSV vector had no
effect on the level of LTR activity in either cell line. In P19
cells, maximum stimulation was seen with about 0.5 mg of
CBFa2-451. Higher levels resulted in decreased levels of trans-
activation. Perhaps excess CBFa2-451 squelched transcription
(2, 36). It is unclear whether saturating levels of CBF a were
attained in the experiments in HeLa cells.
Activity of CBFa2-451 on different core sequences. Core I in
SL3 is conserved in other MuLVs and related type C retrovi-
ruses, while core II is not (10). The sequences of the core
elements in different viruses often vary slightly (10). Notably,
the core of nonleukemogenic Akv virus differs from core I of
SL3 by 1 bp (Fig. 1) (19). This T-C difference has a large effect
on the ability of SL3 to induce T-cell lymphomas (29). It also
affects transcription in T lymphocytes but not other types of
cells (4, 29). CBF from mouse thymocytes was previously
shown to bind both the SL3 and Akv cores (4, 47). Competition
binding experiments by Thornell et al. (47) indicated that CBF
bound preferentially to the SL3 core, although quantitation of
the difference has not been reported. Selected and amplified
binding sequence footprint analysis showed that calf thymus
CBF preferred a T over a C at the corresponding position, but
it preferred C to other bases (24). Like the Akv core, core II of
SL3 has a C at the equivalent position as the T-C difference
between SL3 and Akv (Fig. 1).
To quantify the relative binding of CBF a to the SL3 and
Akv cores, a 17-kDa portion of CBFa2-451 from amino acids
51 through 202 [CBFa2(51-202); Fig. 2] containing the DNA
binding (Runt) domain was PCR amplified and expressed in
E. coli by using a modified pET3 vector system. The protein
was chromatographically enriched to about 20 to 30% purity.
EMSAs were performed with a high-affinity binding site as a
probe (49). Competition experiments were performed with
increasing amounts of the high-affinity site, the SL3 core, the
Akv core, and a mutated core element as competitors (Fig. 4).
The SL3 core element competed for binding about twice as
well as the Akv core, in that approximately twice as much Akv
competitor was needed to decrease binding to the same extent
as the SL3 core site. The high-affinity site competed for binding
about four times more effectively than the SL3 core. The mu-
tated element that contained a crucial C-for-G substitution in
the two adjacent G nucleotides present in the functional CBF
binding sites failed to compete. Thus, CBF can bind to core
sequences that contain a T or C at the position that distin-
guishes SL3 from Akv, but there is a preference for a T.
FIG. 2. Schematic representation of CBFa2-451. t8 and t3 indicate the po-
sitions of the fusion of sequences from chromosomes 8 and 3 in the translocated
forms. Numbers at the top refer to amino acid positions. The black box repre-
sents the Runt domain. CBFa2(51-202) is the portion of CBFa2-451 used in the
binding studies.
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The ability of CBFa2-451 to distinguish the SL3 and Akv
cores was then tested in transcription assays. The activity of
CBFa2-451 was tested by using a recombinant enhancer
(termed SAA; Fig. 1) that was identical to that of SL3 except
for the single base pair found in the core of Akv. This mutation
had no effect on the basal activity of the LTR reporter plasmid
in either P19 or HeLa cells (53). Cotransfection of CBFa2-451
resulted in equivalent levels of stimulation of the viral LTR
whether the core was that of SL3 or Akv (Fig. 3). The simplest
interpretation of this observation is that this form of CBF a is
not solely responsible for the capacity of T cells to distinguish
the SL3 and Akv cores.
One possible explanation for the equivalent activation of the
SL3 and Akv cores by CBF was that the transient expression
assays may have resulted in overexpression of the factor. It was
conceivable that at low, limiting levels of CBF, the difference in
activity between the two cores might be greater. We tested this
possibility by transfecting increasing amounts of CBFa2-451
into L691 T lymphocytes, a cell line in which the SL3 LTR is
about fivefold more active than the SAA LTR. Cotransfection
of increasing amounts of CBFa2-451 failed to alter the activity
of either LTR in transient transfections (Fig. 5). This finding
indicated that the level of this subunit of CBF was not limiting
for the transcriptional activity of these MuLV LTRs in this
T-cell line. It was also consistent with the idea that the equiv-
alent activities of the SL3 and Akv cores in cotransfection
assays were not due to overexpression of CBF that resulted in
driving the SAA LTR activity to that of the SL3 LTR.
It was important to confirm that CBF a was acting through
the core elements in the SL3 enhancer. Mutations were intro-
duced into both copies of core I, both copies of core II, or all
four CBF binding sites simultaneously (Fig. 1A). The 2-bp
mutation in core I was previously shown to block CBF binding
(49), as was the 3-bp mutation in core II (47). These mutations
had no effect on the basal activity of the LTR reporter plasmids
in either P19 or HeLa cells (53). LTRs with these mutations
were tested in cotransfection experiments with CBFa2-451
(Fig. 6). In P19 cells, mutation of core I eliminated all of the
activity of CBFa2-451. This result confirmed that the factor
acts through this site. Mutation of core II also reduced the
level of transactivation by CBFa2-451, but the effect was less
than that seen with core I. The smaller contribution of core II
to the total effect of the SL3 enhancer was consistent with
lower binding affinity for CBF reported by Thornell et al. (47)
and is analogous to the relative effects of mutation of each of
the cores on leukemogenicity of SL3 (13). Simultaneous mu-
tation of the core I and core II sites resulted in lack of trans-
activation in P19 cells.
In HeLa cells, mutation of either core I or core II reduced
the level of transactivation to about threefold (Fig. 6). Simul-
taneous mutation of all four sites reduced the level of trans-
activation to about twofold. Thus, most of the activity of
CBFa2-451 in HeLa cells is indeed through the core elements.
However, there was a residual level of stimulation that was
independent of the cores. To investigate the basis of this, we
also tested a mutated SL3 LTR in which the 59 300 bp includ-
ing essentially the entire enhancer repeat region was deleted
(22). CBFa2-451 also transactivated this LTR about twofold
(53). Thus, a small component of CBF activity on the SL3
reporter construct in HeLa cells was independent of the en-
hancer. It could be due to the factor acting through an un-
known CBF binding site elsewhere in the SL3-CAT plasmid.
However, an equivalent effect was not seen in P19 cells. An
alternative explanation is that CBFa2-451 may have induced
FIG. 3. Titration of CBFa2-451. Increasing amounts of CBFa2-451 were cotransfected with 1.5 mg of the indicated reporter plasmid, and the fold transactivation
was plotted. Datum points are the means of at least two independent trials for each experiment, and error bars show the standard deviations. The total amount of DNA
was kept constant at 8 mg in all experiments by the addition of pBluescript DNA. Transfections were performed in P19 (A) cells and HeLa (B) cells.
VOL. 69, 1995 TRANSCRIPTIONAL ACTIVATION OF CBF ON THE SL3 LTR 2901
the activity of some other factor in HeLa cells that in turn
increased activity of the SL3 promoter-CAT construct. We
note that such a factor would not be active on every transcrip-
tion unit, as we did not detect an effect on the simian virus 40
early enhancer/promoter-luciferase plasmid that was used as
an internal control.
Transcriptional activity of CBF b subunits. There are at
least four different spliced forms of CBF b (Fig. 7). These are
named on the basis of the predicted number of amino acids in
the encoded product. Wang et al. (50) and Ogawa et al. (33)
each identified two subunits, CBF b-187 and CBF b-182, that
differ at their carboxyl termini. While neither CBF b-187 nor
CBF b-182 bound to DNA directly, each could bind to CBF a
subunits through the Runt domain and stimulate DNA binding
activity. Wang et al. (50) also identified a third CBF b isoform
termed CBF b-148. This was identical CBF b-187 except for an
internal deletion of the 39 amino acids encoded in exon 3 due
to alternative splicing. Ogawa et al. (33) identified another
form, here termed CBF b-155, that also differed from CBF
b-187 by an internal deletion due to alternative splicing; how-
ever, the missing sequences were from exon 5. Interestingly,
neither CBF b-148 nor CBF b-155 could bind to CBF a or
stimulate its DNA binding capacity, indicating that there is a
central domain of CBF b that is important for CBF a binding
(12, 33, 50). To examine the effects of CBF b subunits on
transcription, plasmids encoding CBF b-187, CBF b-182, and
CBF b-148 were tested in cotransfection assays using HeLa
and P19 cells. Equal amounts of a CBF b plasmid were co-
FIG. 4. Competition EMSA with E. coli-expressed preparations of the DNA binding domain of CBF a with various enhancer core sequences. (A) A radiolabeled
high-affinity-site probe was used in EMSAs. Increasing amounts of each competitor oligonucleotide were added as indicated (HA, high-affinity site; MUT, mutated site).
In each set of seven lanes from left to right, the competitors were present at 0-, 3-, 6-, 12-, 25-, 50-, and 100-fold molar excess over probe. (B) Percentage of the
protein-DNA complex relative to that with no added competitor DNA versus the amount of competitor DNA. (C) Sequences of one strand of the oligonucleotides used
in this experiment.
FIG. 5. Effects of cotransfection of CBFa2-451 on activity of the SL3 and
SAA LTRs in the T-lymphocyte line L691. LTR-CAT plasmid DNA (3 mg) was
transfected into L691 cells by the DEAE-dextran method (43). Increasing
amounts of CBFa2-451 were cotransfected, and CAT activity was determined.
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transfected with the CBFa2-451-encoding plasmid and the
LTR-CAT plasmid.
Upon the addition of CBF b-187 in HeLa cells, there was a
twofold increase in the level of transactivation over that of
CBFa2-451 alone (Fig. 8). This effect required the CBF a
subunit, as CBF b-187 did not enhance transcription by itself.
In addition, its activity also depended on the presence of both
core elements in the SL3 enhancer, as no effects of the CBF
b-187 were observed when either core was mutated. Thus, at
least in this system, it appeared that CBF b functioned only
when CBFa2-451 could bind to both sites in one repeat.
We also tested whether CBF b-187 could affect the ability of
CBFa2-451 to distinguish the single base pair difference be-
tween the SL3 and Akv cores. Transcription was stimulated
about twofold when the T in the SL3 core I was mutated to the
C in Akv (Fig. 8). Thus, addition of CBF b-187 did not allow
CBFa2-451 to discriminate between the SL3 and Akv core
sites in vivo.
The effect of the CBF b-182 form of CBF b was less clear.
CBF b-182 appeared to stimulate transcription less well than
CBF b-187 but better than CBFa2-451 alone (Fig. 8). This
effect was highly reproducible, as it was seen in every trial that
we performed, regardless of whether the SL3 or Akv core
sequence was present in the reporter construct. However, since
the level of stimulation in some experiments was only about
1.5-fold greater than activity of CBFa2-451 alone, we are un-
certain whether this effect is significant (Fig. 8). CBF b-148
failed to stimulate transcription relative to CBFa2-451 alone.
This is consistent with the inability of this form of CBF b to
associate with CBF a in vitro (50).
When CBF b subunits were coexpressed with CBFa2-451 in
P19 cells, no stimulation of transcription was seen, even with
CBF b-187 (53). Thus, the effects of CBF b differ between the
two cell lines. We do not know the basis for this difference. It
might be the result of different endogenous levels of the b
subunits or differences in the ratios of the different spliced
forms in the two lines. Alternatively, the effect may be the
result of some additional cofactor that might be required for
CBF b activity and is specific for one of the two lines.
DISCUSSION
Our results demonstrate the transcriptional activity of
AML1-encoded CBF a and CBF b on the core elements from
two MuLVs, SL3 and Akv. They are consistent with the idea
that CBF is a factor in T cells that is responsible for recognition
of the viral cores. CBF also binds to the core elements within
the LTR enhancers of other mammalian type C retroviruses
(47). Therefore, it seems likely that CBF will function on the
other MuLV cores.
Mutations within the SL3 core element strongly affect viral
leukemogenicity (13, 29). This can be interpreted to mean that
FIG. 6. Effects of mutation of the SL3 cores on the ability of CBFa2-451 to transactivate the reporter construct. The indicated reporters were cotransfected with
CBFa2-451. The amount of transactivator used in each cell line was based on the titration in Fig. 3. In P19 cells, 0.5 mg of CBFa2-451 was used; in HeLa cells, 4 mg
was used. The means of at least three independent transfections for each experiment are plotted, and the error bars indicate standard deviations.
FIG. 7. Schematic diagram of various spliced forms of CBF b. The amino
and carboxyl termini are indicated. All forms are compared with CBF b-187. The
numbers over the different forms indicate the corresponding amino acid posi-
tions in CBF b-187. The empty spaces show the internal deletions found in CBF
b-148 and CBF b-155, while the hatched box at the C terminus of CBF b-182
indicates different amino acids at this position.
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the transcriptional activity of CBF on the SL3 enhancer is
important for one or more steps in the viral leukemogenic
process in T lymphocytes. However, mutation of the SL3 core
I to that of Akv significantly reduced both the transcriptional
activity in T cells and the capacity to induce T-cell lymphomas
(4, 29). Thus, it is surprising that CBFa2-451 transactivated
both viral cores to the same level. Binding assays have indi-
cated that CBF binds the SL3 core better than that of Akv (24,
47). However, it does bind the Akv sequence (4, 22, 24, 47).
Binding assays presented here indicated that CBF bound the
SL3 core approximately two times better than the Akv core.
The key question is whether this difference in binding is im-
portant for the differential transcription of the two cores.
CBF may still play an important role in the ability of T cells
to distinguish the SL3 and Akv cores, despite the observation
that CBFa2-451 transactivated both viral cores to the same
extent in the cotransfection assays. It is likely that the cotrans-
fection assays do not fully reflect the conditions in T cells.
Thus, additional factors in T cells that bind the SL3 enhancer
may modulate the ability of CBF to distinguish the T-C differ-
ence between the two viral cores. Indeed, previous data indi-
cated that sequences immediately upstream of the core ele-
ment in the SL3 enhancer sequences were important for T cells
to distinguish the two cores (22). Thus, the absence of one of
these factors in HeLa or P19 cells may prevent CBF from
differentiating the viral cores.
It is also possible that the preferential recognition of the SL3
core is actually mediated by a transcription factor other than
CBF. At least two other factors that bind to MuLV core ele-
ments, S-CBF and MCREF-1 (4, 23, 44), have been identified
in T-cell nuclear extracts. If either of these factors is actually
important for distinguishing the SL3 and Akv cores, it would
be necessary to explain how they can act in the presence of
CBF. Perhaps CBF somehow works in combination with one
or more additional core binding factors.
A full description of how transcription factors in T lympho-
cytes recognize MuLV enhancers must account for two obser-
vations. One is the ability of T cells to distinguish the SL3 and
Akv cores. The other is that CBF is present in these cells and
at least certain combinations of CBF a and CBF b are tran-
scriptionally active on both the SL3 and Akv enhancer cores.
Our results also showed that the CBF b-187 form of CBF b
had transcriptional activity. The CBF b-182 form also repro-
ducibly stimulated transcription to a lower level than CBF
b-187, although the effect was small and difficult to measure.
The lower activity of CBF b-182 did suggest that the carboxyl-
terminal amino acids that distinguish CBF b-187 from CBF
b-182 (Fig. 7) have a modest effect on transcription. These
amino acids are replaced by smooth muscle myosin heavy-
chain sequences in human AML (21).
The core site dependence of CBF b transcriptional activity
was consistent with a requirement for it to work by binding to
CBF a. CBF b was previously shown to stimulate the ability of
CBF a to bind DNA (50). Transcriptional stimulation by CBF
FIG. 8. Effects of the multiple forms of CBF b in cotransfection experiments with each of the reporter plasmids in HeLa cells. Each panel shows a specific reporter
construct. The CBF subunits used in each experiment are indicated along the x axis of each panel. When a single CBF subunit was tested, 2.5 mg of the plasmid encoding
it plus 2.5 mg of pBluescript (SK1) were used. When plasmids encoding both CBF subunits were transfected together, 2.5 mg of each was used. The graphs present
the means of at least two independent transfections for each experiment. The error bars indicate standard deviations.
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b may simply reflect this property. However, it is curious that
the effect of CBF b was seen only when both core elements
within each 72-bp repeat in the SL3 enhancer were intact. It is
possible that the stimulation by CBF b-187 on enhancers with
one of the two cores mutated was too small to be detected. On
the other hand, it is also possible that CBF b-187 can stimulate
transcription only when all four binding sites are intact. Per-
haps it has an additional function beyond the stimulation of
CBF a binding. Whatever the mechanism(s), the maximum
activity of CBF in HeLa cells required both subunits.
In addition to its activity on the core elements of two MuLV
enhancers, CBF has been demonstrated to function on the
enhancer of the TCR b chain (2, 34). As similar sequences are
present in the enhancers of many lymphoid cell-specific genes,
it seems likely that this factor regulates the transcription of
many lymphoid genes. CBF binding activity is also present in
nonlymphoid cells. Its potential role in these cells remains to
be investigated.
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